Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.49 |
| ▸ | CDA | P32320 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.40 |
| ▸ | TK2 | O00142 | 2/20 | 0.40 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.40 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.40 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.40 |
| ▸ | ADK | P55263 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9060322 | 1.00 | PYGM (0.49) | PYGMCDAMAPTSLC29A1TK2 | |
| SCHEMBL9063799 | 0.83 | SLC5A2 (0.45) | PYGMCDAMAPT | |
| SCHEMBL9060238 | 0.79 | PYGM (0.58) | PYGMCDAMAPTSLC29A1TK2 | |
| SCHEMBL9060208 | 0.79 | PYGM (0.58) | PYGMCDAMAPTSLC29A1TK2 | |
| SCHEMBL443236 | 0.76 | PYGM (0.43) | PYGMCDAMAPTSLC29A1TK2 | |
| SCHEMBL26970055 | 0.75 | PYGM (0.53) | PYGMCDAMAPTSLC29A1TK2 | |
| SCHEMBL11665141 | 0.75 | MAPT (0.48) | PYGMCDAMAPTSLC29A1SLC28A1 | |
| SCHEMBL5966133 | 0.73 | PYGM (0.41) | PYGMCDAMAPTTK2ADK | |
| SCHEMBL5903974 | 0.71 | PYGM (0.49) | PYGMCDAMAPTSLC29A1SLC28A1 | |
| SCHEMBL5903970 | 0.71 | PYGM (0.49) | PYGMCDAMAPTSLC29A1SLC28A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1996028190-A1 | NON-INVASIVE IMAGING OF GENE TRANSFER | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1996-09-19 | — | — | WO | claimed |